Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (350)	2/22/2003 5:47:34 PM
From: nigel bates	Read Replies (1) of 469

Yes, but not that old, and the puchline's still to come. It's going to be fascinating to see phage go head to head with mouse on the same target, within the same company. Might this suggest that the CAT mab(s) had problems, or would it just be part of the price of a deal with Kirin ? According to the terms of the agreement, Kirin will pay milestone payments and royalties to Human Genome Sciences for any TRAIL-R2 mAb product that is developed and marketed in Japan and Asia/Australasia. Human Genome Sciences will pay royalties to Kirin for any product based on the Kirin TRAIL-R2 mAb that is developed and marketed in Europe, North America and the rest of the world... William A. Haseltine, Ph.D., Chairman and Chief Executive Officer of Human Genome Sciences, said, "We are pleased that we will be working with Kirin to develop and commercialize an agonistic human monoclonal antibody to TRAIL Receptor-2 in Japan and Asia/Australasia. We are also pleased that we will now have the opportunity to study the Kirin antibodies to TRAIL Receptor-2 alongside our own antibody to determine the optimal drug candidate to enter into clinical trials... I wonder if the timescale announced a month before the deal still holds ? - In vitro and in vivo data support Human Genome Sciences' plan to file Investigational New Drug application for TRAIL-R2 agonistic human monoclonal antibody in first half of 2003 -

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next